Smartstream Research Reveals Five Realities Redefining Buy-Side Reconciliations
22.4.2026 11:05:00 EEST | Business Wire | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces new findings from its latest industry research report, Smart Reconciliations: The Buy-Side Perspective, highlighting the structural shifts transforming reconciliation, control, and operational confidence across buy-side firms.
Based on insights gathered from a roundtable of senior operations leaders across asset management and investment firms, the report identifies five critical realities reshaping reconciliation strategies. Despite widespread awareness of rising operational risk, many firms remain constrained by fragmented, reactive, and legacy-driven models.
Buy-side reconciliations is undergoing a fundamental transformation driven by multi-asset expansion, compressed settlement cycles such as T+1, increasing regulatory scrutiny, and growing reliance on third-party providers. These forces are exposing the limitations of traditional batch-based approaches.
The research reveals that over 70% of buy-side firms rely primarily on end-of-day reconciliation, while 53% cite timing differences and data mismatches as the leading causes of breaks. Data quality and availability remain the single largest barriers to achieving effective intraday control.
The five realities shaping buy-side reconciliations:
1. Data integrity risk extends beyond the enterprise
Firms face their greatest data challenges across a complex ecosystem of custodians, brokers, and administrators. 59% of participants identified external data dependencies as the primary risk, while 47% highlighted internal inconsistencies. Incomplete and insufficiently enriched data continues to compound reconciliations pressure, directly impacting liquidity decisions, NAV accuracy, regulatory reporting, and client confidence.
2. T+1 settlement is a systemic stress test
The move to T+1 has transformed reconciliations into a time-critical control function. While 69% of banks report partially adapted models, significant gaps remain in intraday visibility and exception resolution. The result is increased operational risk, particularly in funding and liquidity management.
3. Batch reconciliations is no longer sufficient
Traditional batch processes are increasingly misaligned with today’s transaction complexity and settlement velocity. Only 18% of firms operate near real-time or intraday controls, leaving the majority exposed to late-stage risk and compressed remediation windows. And 53% report rising data mismatches.
4. Third-party oversight remains fragmented
As reliance on external providers grows, accountability and visibility are becoming more opaque. 44% of firms report no significant evolution in oversight models, while data consistency across parties remains the dominant challenge. Leading firms are moving toward independent validation frameworks with full auditability and governance.
5. Efficiency gains depend on data, automation, and AI
Automation is emerging as the primary driver of efficiency, with 62% of firms prioritising a single source of truth. However, sustainable transformation requires more than layering automation onto legacy systems. Firms must first consolidate, normalise, and enrich data to unlock the full value of AI-driven reconciliation and workflow optimisation.
The report highlights a clear shift in leading firms toward repositioning reconciliations as an ‘always-on’ control layer rather than a retrospective, end-of-day checkpoint. This approach enables earlier risk detection, faster decision-making, and stronger operational resilience.
Robin Hasson, Product Management, Smartstream, says: “As buy-side firms navigate increasing complexity and tighter timelines, the ability to establish trusted data foundations and real-time control frameworks is becoming a competitive differentiator. Our report highlights the urgent need for firms to modernise reconciliation strategies to meet the demands of a rapidly evolving financial landscape.”
ABOUT SMARTSTREAM
Smartstream unlocks trusted, intelligent data insights – clearly, consistently, and without compromise.
Empowering leading global financial institutions and enterprises with innovative solutions that deliver accurate, timely data insights to streamline operations, reduce costs, and meet regulatory demands with confidence.
By harnessing data at the core of customer operations, Smartstream drives smarter, faster outcomes across reconciliations, liquidity, collateral, corporate actions, fees, and reference data solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260422712463/en/
Contacts
Shamira Alidina
Media Relations Director
Dina Communications
Email: shamira@dinacomms.com
Nathan Gee
Global Head of Marketing
Smartstream
Email: nathan.gee@smartstream-stp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom